Cancer immunotherapy products: Regulatory aspects in the European Union

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1354-1359

  Camarero, Jorge ^a   Ruiz, Sol ^a  

^a Advanced Therapies and Biotechnology   (Spain)

Author keywords

Cancer vaccine; Immunotherapy; Oncophage; Provenge; Regulatory aspects

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SIPULEUCEL T; VITESPEN;

BIOLOGICAL ACTIVITY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; DRUG STABILITY; DRUG STERILITY; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CARCINOMA; LIFE EXPECTANCY; NOTE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REIMBURSEMENT; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

CANCER VACCINES; EUROPEAN UNION; HUMANS; IMMUNOTHERAPY;

EID: 84866999033     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21142     Document Type: Note

References (27)

1. Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48:237-42; PMID:22030452; http://dx.doi.org/10.1016/j.ejca.2011.09.018.
2. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4.
3. DeFrancesco L. Landmark approval for Dendreon's cancer vaccine. Nat Biotechnol 2010; 28:531-2; PMID:20531312; http://dx.doi.org/10.1038/nbt0610-531.
4. Vaccines for human use. European Pharmacopoeia 2012, 7th edition.
5. www.clinicaltrials.gov (accessed May 31, 2012)
6. www.clinicaltrialsregister.eu/index.html (accessed May 31, 2012)
7. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007; 13:3776-82; PMID:17606707; http://dx.doi.org/ 10.1158/1078-0432.CCR-07-0588.
8. Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388-97; PMID:20826737; http://dx.doi.org/10.1093/jnci/djq310.
9. Regulation (EC) no 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J Eur Union 2004; L136:1-32.
10. Torres F, Calvo G, Pontes C. Methodological recommendations of the regulatory agencies. Med Clin (Barc) 2005; 125(Suppl 1):72-6; PMID:16464431; http://dx.doi.org/10.1016/S0025-7753(05)72213-2.
11. www.ema.europa.eu (accessed June 8, 2001)
12. www.edqm.eu (accessed June 8, 2001)
13. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines /human/medicines /001072/wapp/Initial-authorisation/human-wapp-000003.jsp&mid= WC0b01ac058001d128 (accessed June 4, 2012)
14. Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009; 39:73-80; PMID:19015149; http://dx.doi.org/10.1093/jjco/hyn132.
15. http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/ucm213554.htm (accessed June 4, 2012)
16. April 29, 2010 Approval Letter - Provenge. http://www.fda.gov/ BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215. htm (accessed June 5, 2012)
17. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
18. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al.; C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145-54; PMID:18602688; http://dx.doi.org/10.1016/S0140-6736(08)60697-2.
19. Wood C. A vaccine for renal cancer. Lancet 2008; 372:1460-1; PMID:18970972; http://dx.doi.org/10.1016/S0140-6736(08)61615-3.
20. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union 2007; 324:121-37.
21. The regulator disapproves. Nat Biotechnol 2008; 26:1; PMID:18182998; http://dx.doi.org/10.1038/nbt0108-1.
22. Longo DL. New therapies for castration-resistant prostate cancer. [editorial]. N Engl J Med 2010; 363:479-81; PMID:20818868; http://dx.doi.org/10. 1056/NEJMe1006300.
23. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:273-9; PMID:22232132; http://dx.doi.org/10.1093/jnci/ djr514.
24. Guideline on human cell-based medicinal products (EMEA/CHMP/410869/2006) 2008. http://www.ema.europa.eu/docs /en-GB/document-library/Scientific- guideline/2009/09/WC500003898.pdf
25. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12; PMID:15470213; http://dx.doi.org/10.1056/NEJMoa040720.
26. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59:572-83; PMID:21315502; http://dx.doi.org/10.1016/j.eururo.2011.01.025.
27. Regnstrom J, Koenig F, Aronsson B, Reimer T, Svendsen K, Tsigkos S, et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol 2010; 66:39-48; PMID:19936724; http://dx.doi.org/10.1007/s00228-009- 0756-y.